Akèy › Paragangliom › Maryland
Etid klinik pou Paragangliom nan Maryland
7 etid pou Paragangliom ap chèche patisipan nan sit nan Maryland.
Tèks ofisyèl etid la (Anglè)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Oct 2, 2026 · NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore
- National Institutes of Health ( Site 0125), Bethesda
Ap rekriteFaz 2
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT04924075Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 100 · Tout sèks · Mizajou Aug 25, 2026 · NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1/2
Laj 18 a 120 · Tout sèks · Mizajou Aug 18, 2026 · NCT06427798A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 1
Laj 18 a 120 · Tout sèks · Mizajou Jun 15, 2026 · NCT0604151618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
Ap rekriteFaz 2
Laj 18 a 120 · Tout sèks · Mizajou May 19, 2026 · NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Johns Hopkins, Baltimore
Ap rekriteFaz 1/2
Laj 18 a 90 · Tout sèks · Mizajou May 14, 2026 · NCT05636618Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.